Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

Clinical Microbiology Reviews

Volumn 16, Issue 4, 2003, Pages 569-596

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ACYCLIC NUCLEOSIDE; ADEFOVIR; ADEFOVIR DIPIVOXIL; CIDOFOVIR; GANCICLOVIR; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL; TRIFLURIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CYTOMEGALOVIRUS; DNA VIRUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HEPADNAVIRUS; HEPATITIS B; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NEPHROTOXICITY; NONHUMAN; PAPILLOMA VIRUS; POLYOMA VIRUS; POXVIRUS; RETINITIS; RETROVIRUS; RETROVIRUS INFECTION; REVIEW; SIDE EFFECT; STRAIN DIFFERENCE; VIRUS INFECTION; VIRUS STRAIN;

ADENINE; ANIMALS; CYTOSINE; DNA VIRUS INFECTIONS; DNA VIRUSES; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; REVERSE TRANSCRIPTASE INHIBITORS;

ADENOVIRIDAE; ANIMALIA; COWPOX VIRUS; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HEPADNAVIRIDAE; HEPATITIS B VIRUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MOLLUSCUM CONTAGIOSUM VIRUS; ORF VIRUS; PAPILLOMAVIRUS; POLYOMAVIRUS; POXVIRIDAE; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS; VACCINIA VIRUS; VARIOLA; VARIOLA VIRUS;

EID: 0142126681     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.16.4.569-596.2003     Document Type: Review

References (233)

1. Abdulkarim, B., S. Sabri, E. Deutsch, H. Chagraoui, L. Maggiorella, J. Thierry, F. Eschwege, W. Vainchenker, S. Chouaïb, and J. Bourhis. 2002. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21:2334-2346.
2. 14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 63:678-681.
3. Ambati, J., K. B. Wynne, M. C. Angerame, and M. R. Robinson. 1999. Anterior uveitis associated with intravenous cidofovir in patients with cytomegalovirus retinitis. Br. J. Ophthalmol. 83:1153-1158.
4. Andrei, G., R. Snoeck, D. Schols, and E. De Clercq. 2001. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol. Res. 12:397-408.
5. Andrei, G., R. Snoeck, E. De Clercq, R. Esnouf, P. Fiten, and G. Opdenakker. 2000. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 81:639-648.
6. Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. De Clercq. 1998. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10:523-531.
7. Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. De Clercq. 1998. Inhibitory effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic-nude mice. Oncol. Res. 10:533-539.
8. Andrei, G., R. Snoeck, M. Vandeputte, and E. De Clercq. 1997. Activities of various compounds against murine and primate polyomaviruses. Antimicrob. Agents Chemother. 41:587-593.
9. Angelini, L., M. C. Pietrogrande, M. R. Delle Piane, F. Zibordi, P. Cinque, C. Maccagnano, and L. Vago. 2001. Progressive multifocal leukoencephalopathy in a child with hyperimmunoglobulin E recurrent infection syndrome and review of the literature. Neuropediatrics 32:250-255.
10. Arimilli M. N., C. U. Kim, J. Dougherty, A. Mulato, R. Oliyai, J. P. Shaw, K. C. Cundy, and N. Bischofberger. 1997. Synthesis, in vitro biological evaluation, and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine prodrugs. Antiviral Chem. Chemother. 8:557-564.
11. Armbruster, C., A. Kreuzer, H. Vorbach, M. Huber, and C. Armbruster. 2001. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon α-2b. Eur. Respir. J. 17:830-831.
12. Badiaga, S., P. Parola, C. Zandotti, and P. Brouqui. 1998. Successful treatment of Kaposi's sarcoma with a combination of antiviral drug therapy and chemotherapy: two case reports. Clin. Infect. Dis. 27:1558.
13. Bainbridge, J. W., J. Raina, S. M. Shah, J. Ainsworth, and A. J. Pinching. 1999. Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS. Eye 13:353-356.
14. Balzarini J., J.-F. Navé, M. A. Becker, M. Tatibana, and E. De Clercq. 1995. Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coli, rat liver and human erythrocytes. Nucleosides Nucleotides 14:1861-1871.
15. Banker, A. S., J. F. Arevalo, D. Munguia, F. M. Rahhal, B. Ishimoto, C. Berry, E. De Clercq, R. Ochabski, I. Taskintuna, and W. R. Freeman. 1997. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am. J. Ophthalmol. 124:168-180.
16. Barditch-Crovo, P., J. Toole, C. W. Hendrix, K. C. Cundy, D. Ebeling, H. S. Jaffe, and P. S. Lietman. 1997. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)phosphonylmethoxy-ethyl]adenine) in HIV-infected patients. J. Infect. Dis. 176:406-413.
17. Barouch, D. H., W. C. Faquin, Y. Che, I. J. Koralnik, G. K. Robbins, and B. T. Davis. 2002. BK virus-associated hemorrhagic cystitis in a human immunodeficiency virus-infected patient. Clin. Infect. Dis. 35:326-329.
18. Beadle, J. R., C. Hartline, K. A. Aldern, N. Rodriguez, E. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386.
19. Bendele, R. A., and F. C. Richardson. 2002. Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum. Pathol. 33:574.
20. Benhamou, Y., M. Bochet, V. Thibault, V. Calvez, M. H. Fievet, P. Vig, C. S. Gibbs, C. Brosgart, J. Fry, H. Namini, C. Katlama, and T. Poynard. 2001. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358:718-723.
21. Berenguer, J., J. Mallolas, and the Spanish Cidofovir Study Group. 2000. Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Clin. Infect. Dis. 30:182-184.
22. Bielamowicz, S., V. Villagomez, S. V. Stager, and W. R. Wilson. 2002. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope 112:696-699.
23. Bienvenu, B., F. Martinez, A. Devergie, M. Rybojad, J. Rivet, P. Bellenger, P. Morel, E. Gluckman, and C. Lebbé. 2002. Topical use of cidofovir induced acute renal failure. Transplantation 73:661-662.
24. Birkus, G., I. Votruba, A. Holý, and B. Otová. 1999. 9-[2-(Phosphonomethoxy)ethyl]-adenine diphosphate (PMEApp) as a substrate toward replicative DNA polymerases α, β, ε, and ε*. Biochem. Pharmacol. 58:487-492.
25. Birkus, G., M. Hrijek, P. Kramata, I. Votruba, A. Holý, and B. Otová. 2002. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases α, δ, and ε. Antimicrob. Agents Chemother. 46:1610-1613.
26. Birkus, G., M. J. M. Hitchcock, and T. Cihlar. 2002. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46:716-723.
27. Blick, G., M. Whiteside, P. Griegor, U. Hopkins, T. Garton, and L. LaGravinese. 1998. Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin. Infect. Dis. 26:191-192.
28. Blick, G., T. Garton, U. Hopkins, and L. LaGravinese. 1997. Successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis. J. Acquir. Immun. Defic. Syndr. Hum. Retrovirol. 15:84-85.
29. Blot, N., P. Schneider, P. Young, C. Janvresse, D. Dehesdin, P. Tron, and J. P. Vannier. 2000. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant. 26:903-905.
30. Bordigoni, P., A.-S. Carret, V. Venard, F. Witz, and A. Le Faou. 2001. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 32:1290-1297.
31. Bosi, A., B. Bartolozzi, A. M. Vannucchi, A. Orsi, S. Guidi, and P. Rossi Ferrini. 2002. Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study. Haematologica 87:446-447.
32. Brambella, A. M., A. Castagna, R. Novati, P. Cinque, M. R. Terrini, M. C. Moioli, and A. Lazzarin. 1999. Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. J. Neurol. 246:723-725.
33. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
34. Bray, M., M. Martinez, D. Kefauver, M. West, and R. Roy. 2002. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 54:129-142.
35. Calista, D. 2000. Resolution of recalcitant human papillomavirus gingival infection with topical cidofovir. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 90:713-715.
36. Calista, D. 2000. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J. Eur. Acad. Dermatol. Venereol. 14:484-488.
37. Calista, D., L. Riccioni, and L. Coccia. 2002. Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir. Br. J. Ophthalmol. 86:932-933.
38. Chen, Y., C. Scieux, V. Garrait, G. Socié, V. Rocha, J.-M. Molina, D. Thouvenot, F. Morfin, L. Hocqueloux, L. Garderet, H. Espérou, F. Sélimi, A. Devergie, G. Leleu, M. Aymard, F. Morinet, E. Gluckman, and P. Ribaud. 2000. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin. Infect. Dis. 31:927-935.
39. Cherrington, J. M. 1997. Human cytomegalovirus: resistance profile of cidofovir. Int. Antiviral News 5:91-92.
40. Cherrington, J. M., A. S. Mulato, M. D. Fuller, and M. S. Chen. 1996. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob. Agents Chemother. 40:2212-2216.
41. Cherrington, J. M., R. Miner, M. J. M. Hitchcock, J. P. Lalezari, and W. L. Drew. 1996. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various clinical regimens of drug. J. Infect. Dis. 173:987-992.
42. Chhetri, D. K., J. H. Blumin, N. L. Shapiro, and G. S. Berke. 2002. Office-based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir. Otolaryngol. Head Neck Surg. 126:642-648.
43. Chin, R., T. Shaw, J. Torresi, V. Sozzi, C. Trautwain, T. Bock, M. Manss, H. Isom, P. Furman, and S. Locarnini. 2001. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45:2495-2501.
44. Christensen, N. D., M. D. Pickel, L. R. Budgeon, and J. W. Kreider. 2000. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res. 48:131-142.
45. Christensen, N. D., R. Han, N. M. Cladel, and M. D. Pickel. 2001. Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob. Agents Chemother. 45:1201-1209.
46. Cihlar, T., D. C. Lin, J. B. Pritchard, M. D. Fuller, D. B. Mendel, and D. H. Sweet. 1999. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56:570-580.
47. Cihlar, T., G. Birkus, D. E. Greenwalt, and M. J. M. Hitchcock. 2002. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 54:37-45.
48. Cihlar, T., M. D. Fuller, A. S. Mulato, and J. M. Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382-393.
49. Cihlar, T., I. Votruba, K. Horská, R. Liboska, I. Rosenberg, and A. Holý. 1992. Metabolism of 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in human embryonic lung cells. Collect. Czech. Chem. Commun. 57:661-672.
50. Cihlar, T., and M. S. Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510.
51. Cihlar, T., and M. S. Chen. 1997. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases α, β and γ. Antiviral Chem. Chemother. 8:187-195.
52. Cochereau; I., S. Doan, M.-C. Diraison, H. Mousalatti, N. Guvenisik, L. Ren, and T. Hoang-Xuan. 1999. Uveitis in patients treated with intravenous cidofovir. Ocul. Immunol. Inflammation 7:223-229.
53. Connelly, M. C., B. L. Robbins, and A. Fridland. 1993. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem. Pharmacol. 46:1053-1057.
54. Crippa, F., L. Corey, E. L. Chuang, G. Sale, and M. Boeckh. 2001. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin. Infect. Dis. 32:214-219.
55. Cullen, J. M., D. H. Li, C. Brown, E. J. Eisenberg, K. C. Cundy, J. Wolfe, J. Toole, and C. Gibbs. 2001. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 45:2740-2745.
56. Cundy, K. C. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
57. Cundy, K. C., C. Sueoka, G. R. Lynch, L. Griffin, W. A. Lee, and J.-P. Shaw. 1998. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrob. Agents Chemother. 42:687-690.
58. Dancey, D. R., D. W. Chamberlain, M. Krajden, J. Palefsky, P. W. Alberti, and G. P. Downey. 2000. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir. Chest 118:1210-1214.
59. Davies, E. G., A. Thrasher, K. Lacey, and J. Harper. 1999. Topical cidofovir for severe molluscum contagiosum. Lancet 353:2042.
60. Davis, M. D. P., B. S. Gostout, R. M. McGovern, D. H. Persin, R. L. Schut, and M. R. Pittelkow. 2000. Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy. J. Am. Acad. Dermatol. 43:340-343.
61. De Clercq, E. 1991. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem. Pharmacol. 42:963-972.
62. De Clercq, E. 1993. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3:85-96.
63. De Clercq, E. 1995. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5:149-164.
64. De Clercq E. 1996. Therapeutic potential of cidofovir (HPMPC, Vistide™) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. Verh. K. Acad. Geneeskd. Belg. 58:19-49.
65. De Clercq, E. 1997. Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem? Int. J. Antimicrob. Agents 9:21-36.
66. De Clercq, E. 2001. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:382-397.
67. De Clercq, E. 2002. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55:1-13.
68. De Clercq, E. 2002. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 23:456-458.
69. De Clercq, E., and A. Holý. 1991. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob. Agents Chemother. 35:701-706.
70. De Clercq, E., L. Naesens, L. De Bolle, D. Schols, Y. Zhang, and J. Neyts. 2001. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev. Med. Virol. 11:381-395.
71. Deeks, S. G., A. Collier, J. Lalezari, A. Pavia, D. Rodrigue, W. L. Drew, J. Toole, H. S. Jaffe, A. S. Mulato, P. D. Lamy, W. Li, J. M. Cherrington, N. Hellmann, and J. Kahn. 1997. The safety and efficacy of adefovir dipivoxil, a novel anti-HIV therapy, in HIV infected adults. A randomized, double-blind, placebo controlled trial. J. Infect. Dis. 176:1517-1523.
72. Deeks, S. G., P. Barditch-Crovo, P. S. Lietman, F. Hwang, K. C. Cundy, J. F. Rooney, N. S. Hellmann, S. Safrin, and J. O. Kahn. 1998. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42:2380-2384.
73. Delaugerre, C., A. G. Marcelin, V. Thibault, G. Peytavin, T. Bombled, M.-V. Bochet, C. Katlama, Y. Benhamou, and V. Calvez. 2002. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coninfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob. Agents Chemother. 46:1586-1588.
74. Delmas, J., O. Schorr, C. Jamard, C. Gibbs, C. Trépo, O. Hantz, and F. Zoulim. 2002. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob. Agents Chemother. 46:425-433.
75. De Luca, A., M. Fantoni, T. Tartaglione, and A. Antinori. 1999. Response to cidofovir after failure of antiretrovirat therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 52:891-892.
76. De Luca, A., M. L. Giancola, A. Ammassari, S. Grisetti, A. Cingolani, D. Larussa, L. Alba, R. Murri, G. Ippolito, R. Cauda, A. d'Arminio Monte, and A. Antinori. 2001. Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J. Neurovirol. 7:364-368.
77. De Luca, A., M. L. Giancola, A. Ammassari, S. Grisetti, A. Cingolani, M. G. Paglia, A. Govoni, R. Murri, L. Testa, A. d'Arminio Monforte, and A. Antinori. 2000. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14:F117-F121.
78. De Luca, A., M. L. Giancola, A. Cingolani, A. Ammassari, L. Gillini, R. Murri, and A. Antinori. 1999. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin. Infect. Dis. 28:624-628.
79. de Oliveira, C. B. R., D. Stevenson, L. LaBree, P. J. McDonnell, and M. D. Trousdale. 1996. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res. 31:165-172.
80. Descamps, V., X. Duval, M. Grossin, B. Crickx, and C. Leport. 2001. Topical cidofovir for bowenoid papulosis in an HIV-infected patient. Br. J. Dermatol. 144:628-650.
81. Duan, J., W. Paris, J. De Marte, D. Roopchand, T.-L. Fleet, and M. G. Cordingley. 2000. Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence. Antiviral Res. 46:135-144.
82. Eisenberg, E. J., G.-X. He, and W. A. Lee. 2001. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids 20:1091-1098.
83. Field, A. K., and K. K. Biron. 1994. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 7:1-13.
84. Fife, K., J. Gill, D. Bourboulia, B. Gazzard, M. Nelson, and M. Bower. 1999. Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man. Br. J. Dermatol. 141:1136-1153.
85. Fisher, E. J., K. Chaloner, D. L. Cohn, L. B. Grant, B. Alston, C. L. Brosgart, B. Schmetter, W. M. EI-Sadr, and J. Sampson. 2001. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 15:1695-1700.
86. Foll, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, Z. X. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. 1996. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy) ethyl]adenine (PMEA). Antiviral Res. 32:91-98.
87. Gasnault, J., P. Kousignian, M. Kahraman, J. Rahoiljaon, S. Matheron, J.-F. Delfraissy, and Y. Taoufik. 2001. Cidofovir in AIDS-associated progressive multifocal leuko-encephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J. Neuro virol. 7:375-381.
88. Geerinck, K., G. Lukito, R. Snoeck, R. De Vos, E. De Clercq, Y. Vanrenterghem, H. Degreef, and B. Maes. 2001. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64:543-549.
89. Gilson, R. J., K. B. Chopra, A. M. Newell, I. M. Murray-Lyon, M. R. Nelson, S. J. Rice, R. S. Tedder, J. Toole, H. S. Jaffe, and I. V. D. Weller. 1999. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 6:387-395.
90. González-Fraile, M. I., C. Canizo, D. Caballero, R. Hernández, L. Vázquez, C. López, A. Izarra, J. L. Arroyo, A. de la Loma, M. J. Otero, and J. F. San Miguel. 2001. Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. Transplant. Infect. Dis. 3:44-46.
91. Gordon, Y. J., L. Naesens, E. De Clercq, P. C. Maudgal, and M. Veckeneer. 1996. Treatment of adenoviral conjunctivitis with topical cidofovir. Cornea 15:546.
92. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T.-T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New Engl. J. Med. 348:800-807.
93. + lymphocytopenia: a case report and review of reported cases. Clin. Infect. Dis. 31:e20-e22.
94. Hammoud, Z., D. M. Parenti, and G. L. Simon. 1998. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin. Infect. Dis. 26:1233.
95. Hänel, M., F. Fiedler, and C. Thorns. 2001. Anti-CD20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 24:491-494.
96. Harrigan, P. R., M. D. Miller, P. McKenna, Z. L. Brumme, and B. A. Larder. 2002. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 46:1067-1072.
97. Hengge, U. R., and G. Tietze. 2000. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex. Transm. Infect. 76:143-152.
98. Hillenkamp, J., T. Reinhard, R. S. Ross, D. Bohringer, O. Cartsburg, M. Roggendorf, E. De Clercq, E. Godehardt, and R. Sundmacher. 2001. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch. Ophthalmol. 119:1487-1491.
99. Hillenkamp, J., T. Reinhard, R. S. Ross, D. Bohringer, O. Cartsburg, M. Roggendorf, E. De Clercq, E. Godehardt, and R. Sundmacher. 2002. The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 109:845-850.
100. Ho, H.-T., K. L. Woods, J. J. Bronson, H. De Boeck, J. C. Martin, and M. J. M. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine. Mol. Pharmacol. 41:197-202.
101. Hoffman, J. A., A. J. Shah, L. A. Ross, and N. Kapoor. 2001. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 7:388-394.
102. Hughes, W. T., J. L. Shenep, J. H. Rodman, A. Fridland, R. Willoughby, S. Blanchard, L. Purdue, D. F. Coakley, K. C. Cundy, M. Culnane, B. Zimmer, S. Burchett, J. S. Read, and the Pediatric AIDS Clinical Trials Group. 2000. Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:1041-1046.
103. Ibarra, V., J. R. Blanco, J. A. Oteo, and L. Rosel. 2000. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Dermatol. Venereol. 80:315-316.
104. Jacobson, M. A., S. Wilson, H. Stanley, C. Holtzer, J. Cherrington, and S. Safrin. 1999. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. Clin. Infect. Dis. 28:528-533
105. Johnson, A. A., A. S. Ray, J. Hanes, Z. Suo, J. M. Colacino, K. S. Anderson, and K. A. Johnson. 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276:40848-40857.
106. Julander, J. G., R. W. Sidwell, and J. D. Morrey. 2002. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 55:27-40.
107. Kahn, J., S. Lagakos, M. Wulfsohn, D. Cherng, M. Miller, J. Cherrington, D. Hardy, G. Beall, R. Cooper, R. Murphy, N. Basgoz, E. Ng, S. Decks, D. Winslow, J. J. Toole, and D. Coakley. 1999. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. JAMA 282:2305-2312.
108. Kaufman, H. E., E. D. Varnell, and H. W. Thompson. 1999. Cidofovir and experimental herpetic stromal disease. Arch. Ophthalmol. 117:925-928.
109. Kedes, D. H., and D. Ganem. 1997. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. J. Clin. Investig. 99:2082-2086.
110. Kern, E. R., C. Hartline, E. Harden, K. Keith, N. Rodriguez, J. R. Beadle, and K. Y. Hostetler. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:991-995
111. Kesson, A. M., J. K. Ferguson, W. D. Rawlinson, and A. L. Cunningham. 1997. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin. Infect. Dis. 25:911-914.
112. Kirsch, L. S., J. F. Arevalo, E. Chavez-de-la-Paz, D. Munguia, E. De Clercq, and W. R. Freeman. 1995. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 102:533-542.
113. Kirsch, L. S., J. F. Arevalo, E. De Clercq, E. Chavez-de-la-Paz, D. Munguía, R. Garcia, and W. R. Freeman. 1995. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 119:466-476.
114. Koonsaeng, S., C. Verschraegen, R. Freedman, M. Bossens, A. Kudelka, J. Kavanagh, T. Sittisomwong, E. De Clercq, and R. Snoeck. 2001. Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. J. Med. Virol. 64:195-198.
115. Kopp, T., A. Geusau, A. Rieger, and G. Stingl. 2002. Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient. Br. J. Dermatol. 147:134-138.
116. Kramata, P., I. Votruba, B. Otová, and A. Holý. 1996. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases α, λ and ε. Mol. Pharmacol. 49:1005-1011.
117. Lacy, S. A., M. J. M. Hitchcock, W. A. Lee, P. Tellier, and K. C. Cundy. 1998. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci. 44:97-106.
118. Lalezari, J. P., G. N. Holland, F. Kramer, G. F. McKinley, C. A. Kemper, D. V. Ives, R. Nelson, W. D. Hardy, B. D. Kuppermann, D. W. Northfelt, M. Youle, M. Johnson, R. A. Lewis, D. V. Weinberg, G. L. Simon, R. A. Wolitz, A. E. Ruby, R. J. Stagg, and H. S. Jaffe. 1998. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:339-344.
119. Lalezari, J. P., R. J. Stagg, B. D. Kuppermann, G. N. Holland, F. Kramer, D. V. Ives, M. Youle, M. R. Robinson, W. L. Drew, and H. S. Jaffe. 1997. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 126:257-263.
120. Lalezari, J., T. Schacker, J. Feinberg, J. Gathe, S. Lee, T. Cheung, F. Kramer, H. Kessler, L. Corey, W. L. Drew, J. Boggs, B. McGuire, H. S. Jaffe, and S. Safrin. 1997. A randomized, double-blinded, placebo-controlled trial of cidofovir gel for the treatment of acyclovir unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 176:892-898.
121. Lalezari, J. P., W. L. Drew, E. Glutzer, C. James, D. Miner, J. Flaherty, P. E. Fisher, K. Cundy, J. Hannigan, and J. C. Martin. 1995. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)-propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:788-796.
122. Lalezari, J. P., W. L. Drew, E. Glutzer, D. Miner, S. Safrin, W. F. Owen, Jr., J. M. Davidson, P. E. Fisher, and H. S. Jaffe. 1994. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J. Infect. Dis. 170:570-572.
123. Lateef, F., P. C. Don, M. Kaufmann, S. M. White, and J. M. Weinberg. 1998. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch. Dermatol. 134:1169-1170.
124. Legrand, F., D. Berrebi, N. Houhou, F. Freymuth, A. Faye, M. Duval, J. F. Mougenot, M. Peuchmaur, and E. Vilmer. 2001. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 27:621-626.
125. Lenzo, J. C., G. R. Shellam, and C. M. Lawson. 2001. Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice. Antimicrob. Agents Chemother. 45:1444-1449.
126. Liekens, S., E. Verbeken, E. De Clercq, and J. Neyts. 2001. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int. J. Cancer 92:161-167.
127. Liekens, S., G. Andrei, M. Vandeputte, E. De Clercq, and J. Neyts. 1998. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res. 58:2562-2567.
128. Liekens, S., J. Neyts, E. De Clercq, E. Verbeken, D. Ribatti, and M. Presta. 2001. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res. 61:5057-5064.
129. Ljungman, P., G. L. Deliliers, U. Platzbecker, S. Matthes-Martin, A. Bacigalupo, H. Einsele, J. Ullmann, M. Musso, R. Trenschel, P. Ribaud, M. Bornhäuser, S. Cesaro, B. Crooks, A. Dekker, N. Gratecos, T. Kingebiel, E. Tagliaferri, A. J. Ullmann, P. Wacker, and C. Cordonnier. 2001. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 97:388-392.
130. LoPresti, A. E., J. F. Levine, G. B. Munk, C. Y. Tai, and D. B. Mendel. 1998. Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin. Infect. Dis. 26:512-513.
131. Louie, M., C. Hogan, A. Hurley, V. Simon, C. Chung, N. Padte, P. Lamy, J. Flaherty, D. Coakley, M. Di Mascio, A. S. Perelson, and M. Markowitz. 2003. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 17:1151-1157.
132. Marcellin, P., T.-T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
133. Margot, N. A., E. Isaacsun, I. McGowan, A. K. Cheng, R. T. Schooley, and M. D. Miller. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16:1227-1235.
134. Margot, N. A., E. Isaacson, I. McGowan, A. Cheng, and M. D. Miller. 2003. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J. Acquir. Immune Defic. Syndr. 33:15-21.
135. Matteelli, A., A. Beltrame, S. Graifemberghi, M. A. Forleo, M. Gulletta, G. Ciravolo, S. Tedoldi, C. Casalini, and G. Carosi. 2001. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex. Transm. Dis. 28:343-346.
136. Mazzi, R., S. G. Parisi, L. Sarmati, I. Uccella, E. Nicastri, G. Carolo, F. Gatti, E. Concia, and M. Andreoni. 2001. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS 15:2061-2063.
137. Meadows, K. P., S. K. Tyring, A. T. Pavia, and T. M. Rallis. 1997. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch. Dermatol. 133:987-990.
138. Medveczky, M. M., E. Horvath, T. Lund, and P. G. Medveczky. 1997. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 11:1327-1332.
139. Merta, A., I. Votruba, J. Jindrich, A. Holý, T. Cihlar, I. Rosenberg, M. Otmar, and T. Y. Hervé. 1992. Phosphorylation of 9-(2-phosphonomethoxyethyl)-adenine by AMP(dAMP) kinase from L1210. Biochem. Pharmacol. 44:2067-2077.
140. Miller, M. D., K. E. Anton, A. S. Mulato, P. D. Lamy, and J. M. Cherrington. 1999. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. 179:92-100.
141. Miller, M. D., N. A. Margot, P. D. Lamy, M. D. Fuller, K. E. Anton, A. S. Mulato, and J. M. Cherringon. 2001. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J. Acquir. Immune Defic. Syndr. 27:450-458.
142. Murono, S., N. Raab-Traub, and J. S. Pagano. 2001. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res. 61:7875-7877.
143. Mutimer, D., B. H. Feraz-Neto, R. Harrison, K. O'Donnell, J. Shaw, P. Cane, and D. Pillay. 2001. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 49:860-863.
144. Naeger, L. K., N. A. Margot, and M. D. Miller. 2001. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antiviral Ther. 6:115-126.
145. Naeger, L. K., N. A. Margot, and M. D. Miller. 2001. Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine. Nucleosides Nucleotides Nucleic Acids 20:635-639.
146. Naeger, L. K., N. A. Margot, and M. D. Miller. 2002. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:2179-2184.
147. Naesens, L., R. Snoeck, G. Andrei, J. Balzarini, J. Neyts, and E. De Clercq. 1997. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8:1-23.
148. Nettleton, P. F., J. A. Gilray, H. W. Reid, and A. A. Mercer. 2000. Parapoxviruses are strongly inhibited in vitro by cidofovir. Antiviral Res. 48:205-208.
149. Neyts, J., and E. De Clercq. 1997. Antiviral drug susceptibility of human herpesvirus type 8. Antimicrob. Agents Chemother. 41:2754-2756.
150. Neyts, J., and E. De Clercq. 1993. Efficacy of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:242-246.
151. Neyts, J., and E. De Clercq. 1998. In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents. Antimicrob. Agents Chemother. 42:170-172.
152. Neyts, J., H. Sobis, R. Snoeck, M. Vandeputte, and E. De Clercq. 1993. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihdyroxy-2-propoxymethyl)guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immuno-deficient mice. Eur. J. Clin. Microbiol. Infect. Dis. 12:269-279.
153. Neyts, J., J. Balzarini, L. Naesens, and E. De Clercq. 1992. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J. Med. Virol. 37:67-71.
154. Neyts, J., R. Sadler, E. De Clercq, N. Raab-Traub, and J. S. Pagano. 1998. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res. 58:384-388.
155. Neyts, J., R. Snoeck, D. Schols, J. Balzarini, and E. De Clercq. 1990. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 179:41-50.
156. Neyts, J., R. Snoeck, J. Balzarini, and E. De Clercq. 1991. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antiviral Res. 16:41-52.
157. Noble, S., and K. L. Goa. 1999. Adefovir dipivoxil. Drugs 58:479-487.
158. Orlando, G., M. M. Fasolo, R. Beretta, S. Merli, and A. Cargnel. 2002. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS 16:447-450.
159. Otten, R. A., D. K. Smith, D. R. Adams, J. K. Pullium, E. Jackson, C. N. Kim, H. Jaffe, R. Janssen, S. Butera, and T. M. Folks. 2000. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J. Virol. 74:9771-9775.
160. Palmer, S., N. Margot, H. Gilbert, N. Shaw, R. Buckheit, Jr., and M. Miller. 2001. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes of nucleoside resistance. AIDS Res. Hum. Retroviruses 17:1167-1173.
161. Perrillo, R., E. Schiff, E. Yoshida, A. Statler, K. Hirsch, T. Wright, K. Gutfreund, P. Lamy, and A. Murray. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134.
162. Peters, M. G., G. Singer, T. Howard, S. Jacobsmeyer, X. Xiong, C. S. Gibbs, P. Lamy, and A. Murray. 1999. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient. Transplantation 68:1912-1914.
163. Platzbecker, U., D. Bandt, C. Thiede, A. Helwig, J. Freiberg-Richter, U. Schuler, R. Plettig, G. Geissler, A. Rethwilm, G. Ehninger, and M. Bornhäuser. 2001. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 71:880-885.
164. Plosker, G. L., and S. Noble. 1999. Cidofovir. A review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs 58:325-345.
165. Polis, M. A., K. M. Spooner, B. F. Baird, J. F. Manischewitz, H. S. Jaffe, P. E. Fisher, J. Falloon, R. T. Davey, Jr., J. A. Kovacs, R. E. Walker, S. M. Whitcup, R. B. Nussenblatt, H. C. Lane, and H. Masur. 1995. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother. 39:882-886.
166. Portilla, J., V. Boix, F. Román, S. Reus, and E. Merino. 2000. Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active anti-retroviral therapy. J. Infect. 41:182-184.
167. Pransky, S. M., A. E. Magit, D. B. Kearns, D. R. Kang, and N. O. Duncan. 1999. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch. Otolaryngol. Head Neck Surg. 125:1143-1148.
168. Pransky, S. M., D. F. Brewster, A. E. Magit, and D. B. Kearns. 2000. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 126:1239-1243.
169. Preiser, W., N. Kapur, R. Snoeck, R. W. Groves, and N. S. Brink. 2000. No apparent effect of cidofovir in epidermodysplasia verruciformis. J. Clin. Virol. 16:55-57.
170. Razonable, R. R., A. J. Aksamit, A. J. Wright, and J. W. Wilson. 2001. Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Clin. Proc. 76:1171-1175.
171. Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
172. Redondo, P., M. Idoate, J. C. Galofré, and T. Solano. 2000. Cidofovir inhibits growth of B16 melanoma cells in vivo. Br. J. Dermatol. 143:741-748.
173. Reymen, D., L. Naesens, J. Balzarini, A. Holý, H. Dvoráková, and E. De Clercq. 1995. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res. 28:343-357.
174. Ribaud, P., C. Scieux, F. Freymuth, F. Morinet, and E. Gluckman. 1999. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin. Infect. Dis. 28:690-691.
175. Romanowski, E. G., K. A. Yates, and Y. J. Gordon. 2001. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 52:275-280.
176. Romanowski, E. G., S. P. Bartels, and Y. J. Gordon. 1999. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Investig. Ophthalmol. Visual Sci. 40:378-384.
177. Romanowski, E. G., and Y. J. Gordon. 2000. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Investig. Ophthalmol. Visual Sci. 41:460-463.
178. Sacks, S. L., S. D. Shafran, F. Diaz-Mitoma, S. Trottier, R. G. Sibbald, A. Hughes, S. Safrin, J. Rudy, B. McGuire, and H. S. Jaffe. 1998. A multi-center phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob. Agents Chemother. 42:2996-2999.
179. Salmaggi, A., E. Maccagnano, A. Castagna, S. Zeni, F. Fantini, P. Cinque, and M. Savoiardo. 2001. Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. Neurol. Sci. 22:17-20.
180. Schooley, R. T., P. Ruane, R. A. Myers, G. Beall, H. Lampiris, D. Berger, S.-S. Chen, M. D. Miller, E. Isaacson, and A. K. Cheng. 2002. Tenofovir DF in antirctroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16:1257-1263.
181. Schürmann, D., F. Bergmann, B. Temmesfield-Wollbrück, M. P. Grobusch, and N. Suttorp. 2000. Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS 14:1075-1076.
182. Schürmann, D., F. Bergmann, M. P. Grobusch, M. Behnsch, and A. Liekfeld. 1998. Lack of efficacy of cidofovir in treating AIDS-related cytomegalovirus retinitis after long-term treatment with ganciclovir. AIDS 12:678-679.
183. Shaw J.-P., C. M. Sueoka, R. Oliyai, W. A. Lee, M. N. Arimilli, and K. C. Cundy. 1997. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 14:1824-1829.
184. Shulman, N. S., A. R. Zolopa, D. J. Passaro, J. Murlidharan, D. M. Israelski, C. L. Brosgart, M. D. Miller, S. Van Doren, R. W. Shafer, and D. A. Katzenstein. 2000. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J. Acquir. Immune Defic. Syndr. 23:221-226.
185. Simonart, T., J.-C. Noel, E. De Clercq, and R. Snoeck. 1998. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin. Infect. Dis. 27:1562.
186. Simonart, T., J.-C. Noel, G. De Dobbeleer, D. Parent, J.-P. Van Vooren, E. De Clercq, and R. Snoeck. 1988. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case. J. Med. Virol. 55:215-218.
187. Smee, D. F., J. L. B. Morris, J. A. Leonhardt, J. R. Mead, A. Holý and R. W. Sidwell. 1992. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob. Agents Chemother. 36:1837-1842.
188. Smee, D. F., K. W. Bailey, M.-H. Wong, and R. W. Sidwell. 2001. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 52:55-62.
189. Smee, D. F., K. W. Bailey, M.-H. Wong, and R. W. Sidwell. 2001. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res. 47:171-177.
190. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2001. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chem. Chemother. 12:71-76.
191. Smee, D. F., R. A. Burger, R. P. Warren, K. W. Bailey, and R. W. Sidwell. 1997. An immunosuppressed mouse model of lethal murine gammaherpesvirus 68 infection for studying potential treatment of Epstein-Barr virus infection in man. Antiviral Chem. Chemother. 8:573-581.
192. Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46:1329-1335.
193. Smith, I. L., J. M. Cherrington, R. E. Jiles, M. D. Fuller, W. R. Freeman, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77.
194. KU2 infection of rhesus macaques. Virology 277:306-315.
195. Snoeck, R., G. Andrei, E. De Clercq, M. Gerard, N. Clumeck, G. Tricot, and C. Sadzot-Delvaux. 1993. A new topical treatment for resistant herpes simplex infections. N. Engl. J. Med. 329:968-969.
196. Snoeck, R., J. C. Noël, C. Muller, E. De Clercq, and M. Bossens. 2000. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol. 60:205-209.
197. Snoeck, R., M. Bossens, D. Parent, B. Delaere, H. Degreef, M. Van Ranst, J. C. Noël, M. Wulfsohn, J. F. Rooney, H. S. Jaffe, and E. De Clercq. 2001. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin. Infect. Dis. 33:597-602.
198. Snoeck, R., M. Van Ranst, G. Andrei, E. De Clercq, S. De Wit, M. Poncin, and N. Clumeek. 1995. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N. Engl. J. Med. 333:943-944.
199. Snoeck, R., T. Sakuma, E. De Clereq, I. Rosenberg, and A. Holý. 1988. (S)-1(3-Hydroxy-2-Phosphonylmethoxyprophyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 32:1839-1844.
200. Snoeck, R., W. Wellens, C. Desloovere, M. Van Ranst, L. Naesens, E. De Clercq, and L. Feenstra. 1998. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC]. J. Med. Virol. 54:219-225.
201. Snoeck, R., Y. Van Laethem, E. De Clercq, J. De Maubeuge, and N. Clumeck. 2001. Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. Arch. Intern. Med. 161:2382-2384.
202. Srinivas, R. V., and A. Fridland. 1998. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob. Agents Chemother. 42:1484-1487.
203. Stragier, I., R. Snoeck, E. De Clercq, J. J. Van den Oord, M. Van Ranst, and H. De Greef. 2002. Local treatment of HPV-induced skin lesions by cidofovir. J. Med. Virol. 67:241-245.
204. Reference deleted.
205. Takahashi, K., M. Suzuki, Y. Iwata, S. Shigeta, K. Yamanishi, and E. De Clercq. 1997. Selective activity of various nucleoside and nucleotide analogues against human herpesvirus 6 and 7. Antiviral Chem. Chemother. 8:24-31.
206. Taoufik, Y., J. Gasnault, A. Karaterki, M. P. Ferey, E. Marchadier, C. Goujard, A. Lannuzel, J. F. Delfraissy, and E. Dussaix. 1998. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J. Infect. Dis. 178:1816-1820.
207. Tarantal, A. F., A. Castillo, J. E. Ekert, N. Bischofberger, and R. B. Martin. 2002. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J. Acquir. Immune Defic. Syndr. 29:207-220.
208. Tarantal, A. F., M. L. Marthas, J. P. Shaw, K. Cundy, and N. Bischofberger. 1999. Administration of 9-[2-(R)-(phosphonomethoxy)propyl] adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J. Acquir. Immune Defic. Syndr. 20:323-333.
209. Tatti, K. M., B. E. Korba, H. L. Stang, S. Peek, J. L. Gerin, B. C. Tennant, and R. F. Schinazi. 2002. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antiviral Res. 55:141-150.
210. a.The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. 1997. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann. Intern. Med. 126:264-274.
211. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. 2000. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC peripheral cytomegalovirus retinitis trial. AIDS 14:1571-1581.
212. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. 2001. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the ganciclovir cidofovir cytomegalovirus retinitis trial. Am. J. Ophthalmol. 131:457-467.
213. Toro, J. R., L. V. Wood, N. K. Patel, and M. L. Turner. 2000. Topical cidofovir. A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus type 1. Arch. Dermatol. 136:983-985.
214. Tsai, C.-C., K. E. Follis, A. Sabo, T. W. Beck, R. F. Grant, N. Bischofberger, R. E. Benveniste, and R. Black. 1995. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270:1197-1199.
215. Tsai, C.-C., K. E. Follis, T. W. Beck, A. Sabo, N. Bischofberger, and P. J. Dailey. 1997. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res. Hum. Retroviruses 13:707-712.
216. Tsai, C.-C., P. Emau, J. C. Sun, T. W. Beck, C.-A. Tran, K. E. Follis, N. Bischofberger, and W. R. Morton. 2000. Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J. Med. Primatol. 29:248-258.
217. Van Cutsem, E., R. Snoeck, M. Van Ranst, P. Fiten, G. Opdenakker, K. Geboes, J. Janssens, P. Rutgeerts, G. Vantrappen, and E. De Clercq. 1995. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Med. Virol. 45:230-235.
218. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
219. Van Rompay, K. K. A., M. B. McChesney, N. L. Aguirre, K. A. Schmidt, N. Bischofberger, and M. L. Marthas. 2001. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J. Infect. Dis. 184:429-438.
220. Van Rompay, K. K. A., M. D. Miller, M. L. Marthas, N. A. Margot, P. J. Dailey, D. R. Canfield, R. P. Tarara, J. M. Cherrington, N. L. Aguirre, N. Bischofberger, and N. C. Pedersen. 2000. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]-adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J. Virol. 74:1767-1774.
221. Van Rompay, K. K. A., P. J. Dailey, R. P. Tarara, D. R. Canfield, N. L. Aguirre, J. M. Cherrington, P. D. Lamy, N. Bischofberger, N. C. Pedersen, and M. L. Marthas. 1999. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 73:2947-2955.
222. Van Valckenborgh, I., W. Wellens, K. De Boeck, R. Snoeck, E. De Clercq, and L. Feenstra. 2001. Systemic cidofovir in papillomatosis. Clin. Infect. Dis. 32:e62-e64.
223. Vats, A., R. Shapiro, P. S. Randhawa, V. Scantlebury, A. Tuzuner, M. Saxena, M. L. Moritz, T. J. Beattie, T. Gonwa, M. D. Green, and D. Ellis. 2003. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75:105-112.
224. Walsh, K. M., T. Woodall, P. Lamy, D. G. D. Wight, S. Bloor, and G. J. M. Alexander. 2001. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 49:436-440.
225. Westland, C. E., H. Yang, W. E. Delaney IV, C. S. Gibbs, M. D. Miller, M. Wulfsohn, J. Fry, C. L. Brosgart, and S. Xiong. 2003. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38:96-103.
226. Wilson, W. R., R. Hashemiyoon, and A. Hawrych. 2000. Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report. ENT-Ear Nose Throat J. 79:236-240.
227. Xiong, X., J. L. Smith, and M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:594-599.
228. Yang, H., and R. Datema. 1991. Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice. Antimicrob. Agents Chemother. 35:1596-1600.
229. Yang, H., C. E. Westland, W. E. Delaney IV, E. J. Heathcote, V. Ho, J. Fry, C. Brosgart, C. S. Gibbs, M. D. Miller, and S. Xiong. 2002. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36:464-473.
230. Zabawski, E. J., B. Sands, D. Goetz, M. Naylor, and C. J. Cockerell. 1997. Treatment of verruca vulgaris with topical cidofovir. JAMA 278:1236.
231. Zabawski, E. J., and C. J. Cockerell. 1998. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J. Am. Acad. Dermatol. 39:741-745.
232. Zabawski, E. J., Jr., and C. J. Cockerell. 1999. Topical cidofovir for molluscum contagiosum in children. Pediatr. Dermatol. 16:414-415.
233. Zimmermann, T., K. Stingele, M. Hartmann, J. Haas, R. von Einsiedel, and B. Wildemann. 2001. Succesful treatment of AIDS related PML with HAART and cidofovir. Eur. J. Med. Res. 6:190-192.